Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Medicinal Cannabis, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline.
Last mentioned: Mar 20, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Medicinal Cannabis, the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.8 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6.4 for that window. We currently track 1 Biotech story that mention Bilal Cassim, all published on March 20, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Bilal Cassim. Shared-story counts are live from our verified record — not editorial picks.
Bilal Cassim’s public testimony regarding the efficacy of medicinal cannabis for PTSD and sleep disorders highlights a growing trend of patient-led advocacy in Australia. This case underscores the shifting clinical landscape as researchers and regulators grapple with the integration of cannabinoid therapies into standard psychiatric care.
Bilal Cassim is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
